Sai Life Sciences Limited has informed the Exchange regarding Appointment of Dr. Dinesh V Patel as Independent Director of the company w.e.f. March 24, 2025.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences informed the exchanges that members approved six matters via postal ballot on 16 June 2025. These include ratification of ESOP Scheme 2008 (covering up to 60.99 lakh options, with 64.82 lakh already exercised) and Management ESOP Scheme 2018 (up to 79.45 lakh options, with 12.24 lakh exercised), along with extending these schemes to subsidiary and group company employees. Dr. Dinesh V Patel, a pharma industry veteran with 38 years of experience and current President & CEO of Protagonist Therapeutics, was confirmed as Independent Director for a five-year term from 24 March 2025 to 23 March 2030. Mr. Sivaramakrishnan Chittor, the existing CFO since 2009, was appointed as Whole-Time Director & CFO for a five-year term from 16 June 2025, combining both roles.
These are routine governance and administrative approvals. Dr. Patel adds strong pharma R&D expertise to the board, while the CFO elevation to Whole-Time Director is an internal consolidation. No material impact on shareholders or stock price is expected from these ratifications and appointments.